DEF: Cingulate Inc. 2026 Annual Meeting Proxy Statement

Cingulate Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held on July 9, 2026.

Summary

• The Annual Meeting of Stockholders is scheduled for July 9, 2026, in a virtual-only format.
• Stockholders will vote on the election of Jeff Hargroves as a Class II director.
• The company seeks ratification of KPMG LLP as the independent registered public accounting firm for 2026.
• A proposal is included to amend the 2021 Omnibus Equity Incentive Plan to increase authorized shares by 625,000 to a total of 2,221,126 shares.
• The Board is seeking approval to adjourn the meeting if necessary to solicit additional proxies.
• As of the record date, May 18, 2026, there were 13,469,036 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing focused on governance and compensation, reflecting the company's ongoing efforts to manage its capital structure and retain talent following a recent private placement.

Positives

• The company successfully closed a private placement in February 2026, raising approximately $12.0 million in gross proceeds.
• The company filed the New Drug Application (NDA) for CTx-1301 with the FDA on July 31, 2025.
• The Board has taken steps to rebalance its composition and reduce its size to five directors following the Annual Meeting.

Negatives

• The company has a history of significant salary reductions for executives and employees as a cost-containment measure, though these were reinstated in September 2024.
• The company is heavily reliant on equity-based compensation to attract and retain talent due to its current liquidity position.
• The company has experienced administrative errors resulting in late Section 16(a) filings by certain officers during 2025.

Risks

• The company faces significant retention risk if it cannot provide competitive equity-based compensation.
• The company's liquidity position necessitates the use of equity awards to compensate employees and consultants.
• The company is subject to risks associated with the FDA approval process for its lead product candidate, CTx-1301.
• The company may be unable to secure sufficient votes for the proposed equity plan amendment, which could hinder its ability to attract and retain talent.

Future Outlook

The company intends to continue its focus on the development and commercialization of its pipeline, specifically the CTx-1301 ADHD therapy, and relies on equity-based compensation to maintain its workforce and attract necessary talent.

Management Comments

• The Board believes that the granting of stock options and similar equity-based compensation promotes continuity of management and increases incentive and personal interest in the welfare of the company.
• The company's future success depends on its continued ability to attract, recruit, motivate, and retain high-quality talent.

Industry Context

StockSavvy.ai notes that Cingulate is operating in a capital-intensive biotechnology environment where equity-based compensation is a standard tool for cash-constrained firms to compete for specialized talent while advancing clinical-stage assets.

Comparison to Industry Standards

• The use of an 'evergreen' provision in the equity incentive plan is common among small-cap biotechnology companies to manage share dilution while maintaining flexibility.
• The transition to a virtual-only meeting format is consistent with post-pandemic corporate governance trends for smaller public companies to reduce administrative costs.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Participation of officers and directors in the February 2026 private placement.
• Historical promissory note transactions with WFIA, managed by director Peter Werth.

Stakeholder Impact

• Shareholders are asked to approve an increase in authorized shares, which will result in dilution.
• Employees and directors are the primary beneficiaries of the proposed equity plan amendment.

Next Steps

• Hold the Annual Meeting of Stockholders on July 9, 2026.
• Tabulate and certify votes via Computershare.
• Publish final voting results in a Form 8-K within four business days of the meeting.
• File a registration statement on Form S-8 for the additional shares if the equity plan amendment is approved.

Key Dates

Keywords

Cingulate Inc., Proxy Statement, Equity Incentive Plan, Biotechnology, CTx-1301, Corporate Governance, ADHD therapy